{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:51:28Z","timestamp":1777679488000,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Infantile-onset Pompe disease (IOPD) is a life-threatening lysosomal storage disorder, caused by deficiency of the acid alpha-glucosidase (GAA) enzyme. While enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA) is the standard treatment, its efficacy in cross-reactive immunological material (CRIM)-negative patients is often complicated by severe infusion-associated reactions (IARs), posing significant challenges to management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We present a case of a CRIM-negative IOPD patient carrying a novel homozygous nonsense mutation in the GAA gene (c.2237G\u2009&amp;gt;\u2009A, p.Trp746*). Diagnosis was confirmed by significantly reduced GAA enzyme activity and genetic analysis. The patient was started on ERT using a desensitization protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Despite initial desensitization, the patient experienced recurrent IARs, which progressed to life-threatening anaphylaxis (Grade 5, according to the WAO grading system for allergic reactions). Conventional preventive strategies including corticosteroid premedication, reduction of infusion rate, and dose reduction, failed to prevent the recurrences of severe reactions. A novel approach involving continuous epinephrine co-infusion with low-concentration rhGAA (1\u2005mg\/mL) was subsequently implemented, which may represent a potential rescue strategy to prevent further IARs and allow for continued ERT. Unfortunately, the patient ultimately died from severe pulmonary infection at 15 months of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For CRIM-negative IOPD patients who develop refractory anaphylaxis to ERT, continuous epinephrine co-infusion represents a viable rescue strategy to facilitate treatment. This case underscores the critical need for early immune tolerance induction and the development of novel therapeutic modalities for this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1757529","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:39:49Z","timestamp":1773643189000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of life-threatening anaphylaxis to enzyme replacement therapy in an infant with Pompe disease: a case report and literature review"],"prefix":"10.3389","volume":"7","author":[{"given":"Jueru","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Cardiology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiwei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13052-022-01219-4","article-title":"Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel","volume":"48","author":"Gragnaniello","year":"2022","journal-title":"Ital J Pediatr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e16383","DOI":"10.1111\/ene.16383","article-title":"Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe consortium recommendation update 2024","volume":"31","author":"Schoser","year":"2024","journal-title":"Eur J Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1542\/peds.2016-0280E","article-title":"Management of confirmed newborn-screened patients with Pompe disease across the disease Spectrum","volume":"140","author":"Kronn","year":"2017","journal-title":"Pediatrics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-018-0771-0","article-title":"Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy","volume":"13","author":"Parini","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ajmg.c.31319","article-title":"Predicting cross-reactive immunological material (Crim) status in Pompe disease using Gaa mutations: lessons learned from 10 years of clinical laboratory testing experience","author":"Bali","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World allergy organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/ACI.0000000000000940","article-title":"Biologics to treat anaphylaxis","volume":"23","author":"Yang","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s10072-019-03744-3","article-title":"Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa","volume":"40","author":"Gragnaniello","year":"2019","journal-title":"Neurol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10545-010-9209-0","article-title":"Crim-negative infantile Pompe disease: 42-month treatment outcome","volume":"33","author":"Rohrbach","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s13023-022-02545-w","article-title":"Expert group consensus on early diagnosis and management of infantile-onset Pompe disease in the gulf region","volume":"17","author":"Al-Hassnan","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e94328","DOI":"10.1172\/jci.insight.94328","article-title":"Sustained immune tolerance induction in enzyme replacement therapy\u2013treated Crim-negative patients with infantile Pompe disease","volume":"2","author":"Kazi","year":"2017","journal-title":"JCI Insight"},{"key":"B14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41436-020-01080-y","article-title":"Transforming the clinical outcome in Crim-negative infantile Pompe disease identified via newborn screening. The benefits of early treatment with enzyme replacement therapy and immune tolerance induction","volume":"23","author":"Li","year":"2021","journal-title":"Genet Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3389\/fimmu.2020.01727","article-title":"Benefits of prophylactic short-course immune tolerance induction in patients with infantile Pompe disease: demonstration of long-term safety and efficacy in an expanded cohort","volume":"11","author":"Desai","year":"2020","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","article-title":"Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model","volume":"152","author":"Joseph","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in Crim-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1056\/NEJMoa2407766","article-title":"Aav9-mediated gene therapy for infantile-onset Pompe's disease","volume":"392","author":"Ma","year":"2025","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s10020-025-01090-z","article-title":"Rescue of common and rare exon 2 skipping variants of the Gaa gene using modified U1 Snrna","volume":"31","author":"Peruzzo","year":"2025","journal-title":"Mol Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"eadf1691","DOI":"10.1126\/scitranslmed.adf1691","article-title":"Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders","volume":"16","author":"Ullman","year":"2024","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1757529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:39:51Z","timestamp":1773643191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1757529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":20,"alternative-id":["10.3389\/falgy.2026.1757529"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1757529","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"article-number":"1757529"}}